Penumbra, Inc.

PEN · NYSE · Stock · Healthcare
$320.12
+0.03% today
Delayed price,

What Penumbra does

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Key facts

Sector
Healthcare
Industry
Medical Devices
Market cap
$12.61B
P/E (ttm)
78.7
Forward P/E
52.2
Dividend yield
0.00%
Beta
0.70
Profit margin
10.7%
Employees
4,700
Headquarters
Alameda, CA, United States
Exchange
NYSE

Performance

1 Month
+0.8%
3 Months
+0.6%
6 Months
-3.6%
1 Year
+28.6%
5 Years
+30.3%
$221.2652-week range$362.41
Biggest setback — last 12 months
-11.9%
19 Jan 2026 → 22 Jun 2026
Fell from $359.26 to $316.63 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+58.0%
27 Oct 2025 → 19 Jan 2026
Ran from $227.37 to $359.26 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Below long-term trend
Price sits below its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$303.76 (-5.1%)$320.12$337.37 (+5.4%)
3 Months$292.31 (-8.7%)$320.12$350.58 (+9.5%)
6 Months$281.51 (-12.1%)$320.12$364.03 (+13.7%)
12 Months$266.91 (-16.6%)$320.12$383.93 (+19.9%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 18.2%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.